Caladrius Biosciences Inc., a clinical-stage biopharmaceutical company based in Basking Ridge, has been on the hunt for “strategic development opportunities” this past year, according to President and ...

On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. However, the surge did not come off the back of a treatment’s regulatory ...

Not an acquisition but a “merger of equals.” That’s how Caladrius Biosciences and Cend Therapeutics have described their transformation into the newly christened Lisata Therapeutics. The all-stock ...

Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong ...

As Caladrius Biosciences merges with Cend Therapeutics to become Lisata Therapeutics, it’s leaving a coronary artery disease trial by the wayside. The biotech announced plans to shelve, at least for ...

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are ...

Caladrius reported in May 2020 the compelling positive results of its ESCaPE-CMD Phase 2a study of CLBS16 for the treatment of coronary microvascular dysfunction (“CMD”), a disease that continues to ...